Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801R3O" target="_blank" >RIV/61988987:17110/17:A1801R3O - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/17:00100122 RIV/00843989:_____/17:E0106581

Result on the web

<a href="http://dx.doi.org/10.1136/jclinpath-2017-204329" target="_blank" >http://dx.doi.org/10.1136/jclinpath-2017-204329</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1136/jclinpath-2017-204329" target="_blank" >10.1136/jclinpath-2017-204329</a>

Result language

angličtina

Original language name

Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies

Original language description

Aims Some types of monoclonal gammopathies are typified by a very limited availability of aberrant cells. Modern research use high throughput technologies and an integrated approach for detailed characterisation of abnormal cells. This strategy requires relatively high amounts of starting material which cannot be obtained from every diagnosis without causing inconvenience to the patient. The aim of this methodological paper is to reflect our long experience with laboratory work and describe the best protocols for sample collection, sorting and further preprocessing in terms of the available number of cells and intended downstream application in monoclonal gammopathies research. Potential pitfalls are also discussed.Methods Comparison and optimisation of freezing and sorting protocols for plasma cells in monoclonal gammopathies, followed by testing of various nucleic acid isolation and amplification techniques to establish a guideline for sample processing in haemato-oncology research.Results We show the average numbers of aberrant cells that can be obtained from various monoclonal gammopathies (monoclonal gammopathy of undetermined significance/light chain amyloidosis/multiple myeloma (MM)/MM circulating plasma cells/minimal residual disease MM-10 123/22 846/305 501/68 641/4000 aberrant plasma cells of 48/30/10/16/37x106 bone marrow mononuclear cells) and the expected yield of nucleic acids provided from multiple isolation kits (DNA/RNA yield from 1 to 200x10(3) cells was 2.14-427/0.12-123 ng).Conclusions Tested kits for parallel isolation deliver outputs comparable with kits specialised for just one type of molecule. We also present our positive experience with the whole genome amplification method, which can serve as a very powerful tool to gain complex information from a very small cell population.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

<a href="/en/project/NV17-30089A" target="_blank" >NV17-30089A: In-depth genomic analysis of residual clone in multiple myeloma: approach for individualized targeted therapy</a><br>

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

JOURNAL OF CLINICAL PATHOLOGY

ISSN

0021-9746

e-ISSN

1472-4146

Volume of the periodical

70

Issue of the periodical within the volume

10

Country of publishing house

GB - UNITED KINGDOM

Number of pages

7

Pages from-to

847-853

UT code for WoS article

000411180200006

EID of the result in the Scopus database

2-s2.0-85027239453